TABLE 5.
Proportion of subjects with specific pneumococcal anticapsular IgG concentrations ≥1.0 μg/ml in studies 1 to 3 for the postprimary immunization series (age 7 months)
| Serotype | % of Children (95% CI) with IgG concn ≥1.0 μg/mla
|
|||
|---|---|---|---|---|
| Receiving PncD/T11
|
Not receiving PncD/T11 (study 3 [n = 51]) | |||
| Study 1 (n = 59) | Study 2 (n = 64-69) | Study 3 (n = 41-47) | ||
| TT conjugates | ||||
| 1 | 78 (65-88) | 97 (90-100) | 21 (11-36) | 0 (0-7) |
| 4 | 95 (86-99) | 98 (92-100) | 64 (49-77) | 0 (0-7) |
| 5 | 75 (62-85) | 80 (69-89) | 53 (38-68) | 4 (1-14) |
| 7F | 97 (88-100) | 96 (88-99) | 68 (53-81) | 0 (0-7) |
| 9V | 68 (54-79) | 78 (67-87) | 17 (8-31) | 2 (0-10) |
| 19F | 92 (81-97) | 92 (83-98) | 87 (74-95) | 4 (0-14) |
| 23F | 68 (54-79) | 74 (62-84) | 17 (8-31) | 0 (0-7) |
| DT conjugates | ||||
| 3 | 73 (60-84) | 93 (83-98) | 89 (77-97) | 2 (0-10) |
| 6B | 54 (41-67) | 64 (51-75) | 46 (32-62) | 2 (0-10) |
| 14 | 68 (54-79) | 75 (63-85) | 64 (49-77) | 14 (6-26) |
| 18C | 46 (33-59) | 62 (50-74) | 51 (36-66) | 0 (0-7) |
a
P < 0.001 for all serotypes for the groups that did not receive PncD/T11 compared to each of the three studies in children to whom PncD/T11 was administered; P < 0.001 for serotypes 1, 4, 7F, 9V, and 23F in study 3 versus study 1 and versus study 2 in children receiving PncD/T11; 0.001 < P < 0.05 for serotypes 3 and 5 in study 1 versus study 3 in children receiving PncD/T11; 0.001 < P < 0.05 for serotypes 5 in study 2 versus study 3 in children receiving PncD/T11.